NANOBIOTIX 2020 Q4 and Annual Revenues

Regulatory News:

NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced its revenues for the fourth quarter and full year ended December 31, 2020.

Full Year 2020 Revenue

		Twelve Months Ended December 31st
K€		2020		2019
Revenues		50		68
Of which licenses		-		-
Of which services		50		68
Other sales		-		-

Fourth Quarter 2020 Revenue

In K€		Q4 2020		Q3 2020		Q2 2020		Q1 2020
Revenues		-1.51		14.7		13.4		23.5